194222-05-4

Basic information

• Product Name: 3-exo-Hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester
• Synonyms: 3-exo-Hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester;Tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate;TERT-BUTYL 3-EXO-HYDROXY-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE;8-azabicyclo[3.2.1]octane-8-carboxylic acid, 3-hydroxy-, 1,1-dimethylethyl ester, (3-exo)-;(1R,3s,5S)-tert-Butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate;(1R,3s,5S);tert-Butyl (1R,3s,5S)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate
• CAS NO: 194222-05-4
• Molecular Formula: C₁₂H₂₁NO₃
• Molecular Weight: 227
• Mol File: 194222-05-4.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-exo-Hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-exo-Hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester(194222-05-4)
• EPA Substance Registry System: 3-exo-Hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester(194222-05-4)

Safety Data

• Hazardous Substances Data: 194222-05-4(Hazardous Substances Data)

Usage

General Description

3-exo-Hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester is a chemical compound with the molecular formula C12H21NO3. It is a tert-butyl ester derivative of 3-exo-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid and is commonly used as a building block in the synthesis of various pharmaceutical compounds. 3-exo-Hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester is a bicyclic structure containing a tertiary amine and a carboxylic acid functional group, making it useful in medicinal chemistry research and drug development. Its unique structure and functional groups make it a valuable intermediate for the production of potential pharmaceutical substances.

Upstream product

• 652148-00-0 8-(4-fluoro-benzyl)-8-aza-bicyclo[3.2.1]octan-3-ol 
• 34619-03-9 tert-butyldicarbonate 
• 185099-67-6 N-Boc-nortropinone 
• 185099-67-6 Boc-tropinone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 28957-72-4 N-benzylnortropinone 

Downstream Products

• 652148-01-1 tert-butyl (1R,3r,5S)-3-[4-fluorophenoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 944123-76-6 1,1-Dimethylethyl 3-[(phenylmethyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 945565-37-7 exo tert-butyl 3-(3-bromo-5-cyanophenoxy)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 1206177-12-9 C₂₄H₂₈FN₅O₅S 
• 1206177-42-5 C₂₅H₃₂ClFN₄O₅S 
• 1442691-54-4 tert-butyl (1R,3r,5S)-3-[4-chlorophenoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 1147552-28-0 C₂₄H₂₅FN₄O₄S 
• 1147552-98-4 C₂₂H₂₇FN₄O₅S₂ 
• 1147552-71-3 C₂₁H₂₄ClN₃O₄S 
• 1147552-73-5 C₂₂H₂₄N₄O₄S 
• 1147552-75-7 C₂₂H₂₃ClN₄O₄S 
• 1147552-87-1 C₂₂H₂₅N₅O₃S 
• 1147552-88-2 C₂₂H₂₄FN₅O₃S 
• 1147553-00-1 C₂₂H₂₄FN₅O₃S 

Relevant articles and documents

Bioorthogonal Self-Immolative Linker Based on Grob Fragmentation

A self-immolative bioorthogonal conditionally cleavable linker based on Grob fragmentation is described. It is derived from 1,3-aminocyclohexanols and allows the release of sulfonate-containing compounds in aqueous media. Modulation of the amine pKa promo

MODULATION OF N-ACYLETHANOLAMINE-HYDROLYSING ACID AMIDASE (NAAA) FOR DISEASE TREATMENT

Pharmaceutical compositions make up a compound acting as inhibitor of N-acylethanolamine-hydrolysing acid amidase (NAAA), may be used for the therapeutical treatment and prevention of pain and inflammatory disorders and other disorders which benefit from

CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS

This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.